Search Results - "Fenaux, Pierre"

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial

Oliva, Esther Natalie, Platzbecker, Uwe, Garcia-Manero, Guillermo, Mufti, Ghulam J., Santini, Valeria, Sekeres, Mikkael A., Komrokji, Rami S., Shetty, Jeevan K., Tang, Derek, Guo, Shien, Liao, Weiqin, Zhang, George, Ha, Xianwei, Ito, Rodrigo, Lord-Bessen, Jennifer, Backstrom, Jay T., Fenaux, Pierre

27

Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial

Garcia-Manero, Guillermo^{Aff1, IDs12325025032085_cor1}, Santini, Valeria, Zeidan, Amer M., Komrokji, Rami S., Pozharskaya, Veronika, Rose, Shelonitda, Keeperman, Karen, Lai, Yinzhi, Kalsekar, Sameer, Aggarwal, Barkha, Miteva, Dimana, Valcárcel, David, Fenaux, Pierre, Shortt, Jake, Della Porta, Matteo Giovanni, Platzbecker, Uwe

Mutant p53 regulates a distinct gene set by a mode of genome occupancy that is shared with wild type

Rahmé, Ramy^{Aff1, Aff2, Aff3}, Resnick-Silverman, Lois, Anguiano, Vincent^{Aff1, Aff4}, Campbell, Moray J, Fenaux, Pierre^{Aff2, Aff6}, Manfredi, James J^{Aff1, Aff4, IDs4431902500375y_cor1}

A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome

Garcia-Manero, Guillermo^{Aff1, IDs00277024060814_cor1}, Gaddh, Manila, Platzbecker, Uwe, Lindsley, R. Coleman, Larson, Sarah M., Chevassut, Timothy, Fenaux, Pierre, Komrokji, Rami, Lyons, Roger, Al-Kali, Aref, Jiang, Yu, Bothos, John, Townsley, Danielle M., Zeidan, Amer M.

Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study

Rabian, Florence, Chevret, Sylvie, Gruson, Bérengère, Thépot, Sylvain, Walter-Petrich, Anouk, Braun, Thorsten, Vey, Norbert, Torregrosa-Diaz, José Miguel, Peterlin, Pierre, Toma, Andrea, D’Aveni, Maud, Delaunay, Jacques, Legros, Laurence, Droin, Nathalie, Chermat, Fatiha, Lusina, Daniel, Adès, Lionel^{Aff1, Aff16}, Sapena, Rosa, Solary, Eric, Fenaux, Pierre^{Aff1, Aff16}, Itzykson, Raphael^{Aff1, Aff16, IDs41375024024028_cor21}

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

Crisà, Elena^{Aff1, Aff2, IDs41375024023601_cor1}, Mora, Elvira, Germing, Ulrich, Bally, Cecile, Diez Campelo, Maria, Myllymäki, Mikko, Jädersten, Martin, Komrokji, Rami, Platzbecker, Uwe, Haase, Detlef, Hofmann, Wolf-Karsten, Al Ali, Najla H., Barraco, Daniela^{Aff2, Aff13}, Bargay, Juan José, Bernal, Teresa, López Cadenas, Felix, Calvisi, Anna^{Aff2, Aff17}, Capodanno, Isabella^{Aff2, Aff18}, Cerrano, Marco^{Aff19, Aff20}, Ciancia, Rosanna^{Aff2, Aff21}, Crugnola, Monica^{Aff2, Aff22}, Kündgen, Andrea, Finelli, Carlo^{Aff2, Aff23}, Fozza, Claudio^{Aff2, Aff24}, Frairia, Chiara^{Aff2, Aff20}, Freja, Ebeling, Ganster, Christina, Kubasch, Anne Sophie, Jimenez, Maria Jose, Latagliata, Roberto, Hernandez Mohedo, Francisca, Molero, Antonieta, Vara Pampliega, Miriam, Perez, Clara Aparicio, Pietrantuono, Giuseppe^{Aff2, Aff32}, Poloni, Antonella^{Aff2, Aff33}, Pomares, Helena, Recasens, Valle, Rüfer, Axel, Signori, Alessio, Hellstrom-Lindberg, Eva, Fenaux, Pierre, Sanz, Guillermo^{Aff6, Aff39}, Santini, Valeria^{Aff2, Aff40, IDs41375024023601_cor44}

Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen

Robin, Marie^{Aff1, IDs41409024023142_cor1}, Nibourel, Olivier, Tournaire, Martin, Michonneau, David, Preudhomme, Claude, Verbanck, Marie, Xhaard, Aliénor, Adès, Lionel, Sicre de Fontbrune, Flore, Sébert, Marie, Fenaux, Pierre, Socié, Gérard, Peffault de Latour, Régis, Curis, Emmanuel^{Aff3, Aff5}

Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells

Maslah, Nabih^{Aff1, Aff2, IDs4137502402281z_cor1}, Rety, Salome, Bonnamy, Melina, Aguinaga, Lorea, Huynh, Tony, Parietti, Veronique, Giraudier, Stephane^{Aff1, Aff2}, Fenaux, Pierre^{Aff3, IDs4137502402281z_cor8}, Cassinat, Bruno^{Aff1, Aff2}

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.

de Botton, Stéphane, Fenaux, Pierre, Yee, Karen, Récher, Christian, Wei, Andrew, Montesinos, Pau, Taussig, David, Pigneux, Arnaud, Braun, Thorsten, Curti, Antonio, Grove, Carolyn, Khwaja, Asim, Legrand, Ollivier, Peterlin, Pierre, Arnan, Montserrat, Blum, William, Cilloni, Daniela, Hiwase, Devendra, Jurcic, Joseph, Krauter, Jürgen, Thomas, Xavier, Watts, Justin, Yang, Jay, Polyanskaya, Olga, Brevard, Julie, Sweeney, Jennifer, Barrett, Emma, Cortes, Jorge, Jonas, Brian

application/pdf

Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation

Rombaut, David^{Aff1, Aff2, Aff3, Aff4}, Lefèvre, Carine^{Aff1, Aff2, Aff3}, Rached, Tony^{Aff1, Aff2}, Bondu, Sabrina^{Aff1, Aff2}, Letessier, Anne, Mangione, Raphael M., Farhat, Batoul^{Aff1, Aff2}, Lesieur-Pasquier, Auriane^{Aff1, Aff2}, Castillo-Guzman, Daisy, Boussaid, Ismael^{Aff1, Aff2, Aff4}, Friedrich, Chloé^{Aff1, Aff2, Aff4}, Tourville, Aurore^{Aff1, Aff2}, De Carvalho, Magali^{Aff1, Aff2}, Levavasseur, Françoise^{Aff1, Aff2}, Leduc, Marjorie^{Aff1, Aff7}, Le Gall, Morgane^{Aff1, Aff7}, Battault, Sarah^{Aff1, Aff2}, Temple, Marie, Houy, Alexandre, Bouscary, Didier^{Aff1, Aff9}, Willems, Lise^{Aff1, Aff9}, Park, Sophie, Raynaud, Sophie, Cluzeau, Thomas, Clappier, Emmanuelle, Fenaux, Pierre, Adès, Lionel, Margueron, Raphael, Wassef, Michel, Alsafadi, Samar, Chapuis, Nicolas^{Aff1, Aff4}, Kosmider, Olivier^{Aff1, Aff2, Aff4}, Solary, Eric, Constantinou, Angelos, Stern, Marc-Henri, Droin, Nathalie, Palancade, Benoit, Miotto, Benoit, Chédin, Frédéric, Fontenay, Michaela^{Aff1, Aff2, Aff3, Aff4, IDs41467024465477_cor40}

VAE-Surv: A novel approach for genetic-based clustering and prognosis prediction in myelodysplastic syndromes

Rollo, Cesare ^a, Pancotti, Corrado ^{a, 1}, Sartori, Flavio ^a, Caranzano, Isabella ^a, D’Amico, Saverio ^{b, c}, Carota, Luciana ^d, Casadei, Francesco ^e, Birolo, Giovanni ^a, Lanino, Luca ^b, Sauta, Elisabetta ^b, Asti, Gianluca ^b, Buizza, Alessandro ^b, Delleani, Mattia ^{b, c}, Zazzetti, Elena ^b, Bicchieri, Marilena ^b, Maggioni, Giulia ^b, Fenaux, Pierre ^f, Platzbecker, Uwe ^g, Diez-Campelo, Maria ^h, Haferlach, Torsten ⁱ, Castellani, Gastone ^{d, j}, Della Porta, Matteo Giovanni ^{b, k}, Fariselli, Piero ^{a, ⁎}, Sanavia, Tiziana ^a

Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens

Sébert, Marie^{Aff1, Aff2, Aff3, IDs41375024021803_cor1}, Freiman, Lucie, Chaffaut, Cendrine, Guerci, Agnès^{Aff3, Aff5}, Peterlin, Pierre^{Aff3, Aff6}, Thépot, Sylvain^{Aff3, Aff7}, Beyne-Rauzy, Odile^{Aff3, Aff8}, Park, Sophie^{Aff3, Aff9}, Cluzeau, Thomas^{Aff3, Aff10}, Chermat, Fatiha, Fenaux, Pierre^{Aff1, Aff2, Aff3}, Preudhomme, Claude, Clappier, Emmanuelle^{Aff1, Aff12}, Chevret, Sylvie, Adès, Lionel^{Aff1, Aff2, Aff3}, Duployez, Nicolas^{Aff1, Aff11, Aff12}, Duchmann, Matthieu^{Aff1, Aff12, IDs41375024021803_cor17}

Germline CHEK2 mutations in patients with myeloid neoplasms

Freiman, Lucie^{Aff1, Aff2}, Larcher, Lise^{Aff1, Aff3, Aff4}, Tueur, Giulia, Vasquez, Nadia, Da Costa, Mélanie, Duchmann, Matthieu^{Aff1, Aff3, Aff4}, Raffoux, Emmanuel, Adès, Lionel^{Aff1, Aff2, Aff4}, Fenaux, Pierre^{Aff1, Aff2, Aff4}, Soulier, Jean^{Aff1, Aff3, Aff4}, Duployez, Nicolas^{Aff1, Aff3, Aff5}, Clappier, Emmanuelle^{Aff1, Aff3, Aff4}, Sébert, Marie^{Aff1, Aff2, Aff4, IDs4137502402179w_cor13}

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Borate, Uma ^{1, ∗}, Pugh, Kelly ¹, Waller, Allyson ¹, Welkie, Rina Li ¹, Huang, Ying ¹, Bewersdorf, Jan Philipp ², Stahl, Maximilian ³, DeZern, Amy E. ⁴, Platzbecker, Uwe ⁵, Sekeres, Mikkael A. ⁶, Wei, Andrew H. ⁷, Buckstein, Rena J. ⁸, Roboz, Gail J. ⁹, Savona, Michael R. ¹⁰, Loghavi, Sanam ¹¹, Hasserjian, Robert P. ¹², Fenaux, Pierre ¹³, Sallman, David A. ¹⁴, Hourigan, Christopher S. ¹⁵, Della Porta, Matteo Giovanni ¹⁶, Nimer, Stephen ⁶, Little, Richard F. ¹⁷, Santini, Valeria ¹⁸, Efficace, Fabio ¹⁹, Taylor, Justin ⁶, Garcia-Manero, Guillermo ²⁰, Odenike, Olatoyosi ²¹, Kim, Tae Kon ¹⁰, Halene, Stephanie ², Komrokji, Rami S. ¹⁴, Griffiths, Elizabeth A. ²², Greenberg, Peter L. ²³, Xu, Mina L. ²⁴, Xie, Zhuoer ¹⁴, Bejar, Rafael ²⁵, Sanz, Guillermo F. ^{26, 27, 28}, Patnaik, Mrinal M. ²⁹, Figueroa, Maria ⁶, Carraway, Hetty E. ³⁰, Abdel-Wahab, Omar ³¹, Starczynowski, Daniel ³², Padron, Eric ¹⁴, Boultwood, Jacqueline ³³, Gore, Steven ¹⁷, Daver, Naval G. ²⁰, Churpek, Jane E. ³⁴, Majeti, Ravindra ²³, Bennett, John M. ³⁵, List, Alan F. ³⁶, Brunner, Andrew M. ³⁷, Zeidan, Amer M. ²

Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet

Ribrag, Vincent ^{a, b, *}, Bron, Dominique ^c, Rymkiewicz, Grzegorz ^d, Hoelzer, Dieter ^f, Jørgensen, Judit ^g, de Armas-Castellano, Aythami ^h, Trujillo-Martín, Maria ^{h, i}, Fenaux, Pierre ^{j, k}, Malcovati, Luca ^{l, m}, Bolaños, Natacha ⁿ, Ribera, Josep-Maria ^o, Herbaux, Charles ^p, Sarkozy, Clémentine ^q, Zinzani, Pier Luigi ^r, Walewski, Jan ^e, Chamuleau, Martine E D ^s

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study

Gravdahl Garelius, Hege Kristin ^{a, *}, Bagguley, Timothy ^b, Taylor, Adele ^b, Fenaux, Pierre ^c, Bowen, David ^d, Symeonidis, Argiris ^e, Mittelmann, Moshe ^f, Stauder, Reinhard ^g, Čermák, Jaroslav ^h, Sanz, Guillermo ⁱ, Langemeijer, Saskia ^j, Malcovati, Luca ^k, Germing, Ulrich ^l, Sanhes, Laurence ^m, d'Aveni, Maud ⁿ, Culligan, Dominic ^o, Kotsianidis, Ioannis ^p, Koinig, Karin A ^g, van Marrewijk, Corine ^j, Crouch, Simon ^b, deWitte, Theo ^j, Smith, Alexandra ^{b, *}, Hellström-Lindberg, Eva ^{q, *}

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from the FRENVEX group

Adès, Lionel, Ame, Shanti, Antoine, Carole, Ardois, Samuel, Arnaud, Laurent, Audemard, Alexandra, Belot, Alexandre, Benhamou, Ygal, Besançon, Anne, Bescond, Charles, Borie, Raphael, Bouaziz, Jean David, Bourguiba, Rim, Bouzy, Simon, Broner, Jonathan, Buchonnet, Gérard, Foucher, Barbara Buono, Carpentier, Benjamin, Cauchois, Raphael, Chasset, François, Clappier, Emmanuelle, Cornet, Edouard, Coustal, Cyrille, Crickx, Etienne, Daliphard, Sylvie, De Mas, Véronique, De Renzis, Benoit, De Sainte Marie, Benjamin, Defasque, Sabine, Delhommeau, François, Denis, Guillaume, Dieval, Celine, Djobo, Christine, Dragani, Matteo, Duployez, Nicolas, Ebbo, Mikael, El-Karoui, Khalil, Etancelin, Pascaline, Eveillard, Marion, Farnault, Laure, Flamarion, Edouard, Freynet, Nicolas, Friedrich, Chloe, Gelsi-Boyer, Véronique, Godmer, Pascal, McAvoy, Chloé, Gonçalves Monteiro, Valerie, Gourguechon, Clément, Gourin, Marie Pierre, Grosleron, Sylvie, Guenot, Cécile, Guilpain, Philippe, Hage-Sleiman, Mehdi, Herlem, Julien, Jallades, Laurent, Jamilloux, Yvan, Langlois, Vincent, François Lesesve, Jean, Liferman, François, Lobbes, Hervé, Maloum, Karim, Thibault Jacques Maria, Alexandre, Guingel, Paola Marianetti, Mathian, Alexis, Melki, Isabelle, Mohty, Bilal, Morel, Alexandre, Moulinet, Thomas, Palat, Sylvain, Pannetier, Mélanie, Perlat, Antoinette, Peterlin, Pierre, Quint, Laurent, Rauzy, Odile, Rivoli, Giulia, Roux-Sauvat, Marielle, Russello, Jennifer, Sauvetre, Gaetan, Schmit, Stéphanie, Sciortino, Didier, Stamatoulla, Aspasia, Terriou, Louis, Torregrosa-Diaz, Jose-Miguel, Trimoreau, Franck, Veronese, Lauren, Vinit, Julien, Woaye-Hune, Pascal, Jachiet, Vincent ^{1, ∗}, Kosmider, Olivier ², Beydon, Maxime ³, Hadjadj, Jérôme ¹, Zhao, Lin Pierre ⁴, Grobost, Vincent ⁵, Lacombe, Valentin ⁶, Le Guenno, Guillaume ⁵, Nguyen, Yann ⁷, Arlet, Jean Benoit ⁸, Dion, Jérémie ⁹, Heiblig, Mael ¹⁰, Garnier, Alice ¹¹, Samson, Maxime ¹², Aouba, Achille ¹³, Thepot, Sylvain ¹⁴, Dimicoli-Salazar, Sophie ¹⁵, Dutasta, Fabien ¹⁶, Faucher, Benoît ¹⁷, Lazaro, Estibaliz ¹⁸, Morel, Véronique ¹⁹, Neel, Antoine ²⁰, Outh, Roderau ²¹, Bezanahary, Holy ²², Rossignol, Julien ²³, Alary, Anne Sophie ²⁴, Bidet, Audrey ²⁵, Blateau, Pauline ²⁶, Bouvier, Anne ²⁷, Boursier, Guilaine ^{28, 29}, Decamp, Matthieu ³⁰, Lebecque, Benjamin ³¹, Le Bris, Yannick ³², Sujobert, Pierre ³³, Marceau-Renaut, Alice ³⁴, Pastoret, Cédric ³⁵, Rizzo, David ³⁶, Boiret-Dupre, Nathalie ³¹, Boucher, Lara ², Dulucq, Stéphanie ²⁵, Genevieve, Franck ²⁷, Jadeau, Cassandra ³⁶, Lemaire, Pierre ³⁷, Vazquez, Romain ², Rieu, Jean Baptiste ³⁸, Fain, Olivier ¹, Georgin-Lavialle, Sophie ³⁹, Rigolot, Lucie ³⁸, Larcher, Lise ³⁷, Hirsch, Pierre ⁴⁰, Terrier, Benjamin ⁴¹, Fenaux, Pierre ⁴, Mekinian, Arsène ¹, Comont, Thibault ⁹

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS

DeZern, Amy E. ^{1, ∗}, Thepot, Sylvain ², de Botton, Stephane ³, Patriarca, Andrea ⁴, Deeren, Dries ⁵, Torregrossa-Diaz, Jose-Miguel ⁶, Marconi, Giovanni ⁷, Bernal, Teresa ⁸, Bergua Burgues, Juan ⁹, Xicoy, Blanca ¹⁰, Jonášová, Anna ¹¹, Zeidan, Amer M. ¹², Dimicoli-Salazar, Sophie ¹³, Simand, Célestine ¹⁴, Valcarcel, David ¹⁵, Diez Campelo, Maria ¹⁶, Chai-Ho, Wanxing ¹⁷, Saini, Lalit ¹⁸, Garnier, Alice ¹⁹, Geissler, Klaus ²⁰, Ofran, Yishai ²¹, Nagy, Zsolt ²², Krishnamurthy, Pramila ²³, Lübbert, Michael ²⁴, Basak, Grzegorz ²⁵, Carraway, Hetty E. ²⁶, Sallman, David A. ²⁷, Borate, Uma ²⁸, Santini, Valeria ²⁹, Campbell, Victoria ³⁰, Fenaux, Pierre ³¹, Braun, Thorsten ³², Lanza, Francesco ³³, Zaucha, Jan Maciej ³⁴, Roth, David A. ³⁵, Paul, Sofia ³⁵, Roy, Pourab ³⁵, Kelly, Michael J. ³⁵, Volkert, Angela ³⁵, Chisholm, Jaime ³⁵, Malak, Tanya Abdul ³⁵, Klimek, Virginia M. ³⁵, Cluzeau, Thomas ³⁶

Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine

Zhao, Lin-Pierre ^{1, 2, 3}, Dumas-Rivero, Typhaine ^{1, 2, 4}, Barette, Lauren ^{2, 3}, Aguinaga, Lorea ^{2, 3}, Cheffai, Arij ^{2, 3}, Chauvel, Clémentine ^{2, 4}, Dal Bello, Reinaldo ^{2, 5}, Raffoux, Emmanuel ^{2, 5}, Clappier, Emmanuelle ^{1, 2, 4}, Duchmann, Matthieu ^{1, 2, 4}, Fenaux, Pierre ^{1, 2, 3}, Lemaire, Pierre ^{2, 4}, Mathis, Stephanie ^{2, 4}, Sébert, Marie ^{1, 2, 3}, Adès, Lionel ^{1, 2, 3}, Itzykson, Raphaël ^{1, 2, 5, ∗}

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Daver, Naval ^{1, ∗}, Vyas, Paresh ², Huls, Gerwin ³, Döhner, Hartmut ⁴, Maury, Sébastien ⁵, Novak, Jan ⁶, Papayannidis, Cristina ⁷, Martínez Chamorro, Carmen ⁸, Montesinos, Pau ⁹, Niroula, Rabin ¹⁰, Fenaux, Pierre ¹¹, Esteve, Jordi ¹², Wu, Shang-Ju ¹³, De Voeght, Adrien ¹⁴, Mayer, Jiri ¹⁵, Valk, Peter J. M. ¹⁶, Johnson, Lisa ¹⁷, Dong, Mei ¹⁷, Liu, Ke ¹⁷, Kuwahara, Sowmya ¹⁷, Caldwell, Kenneth ¹⁷, Guru Murthy, Guru Subramanian ¹⁸